Key takeaways
- mRNA cancer vaccines are mostly treatment vaccines: they teach the immune system to recognize markers on a person’s tumour. They do not prevent cancer.
- On August 19, 2026, Merck and Moderna announced the first positive Phase 3 result for an mRNA cancer vaccine, intismeran plus Keytruda, in 1,137 people with surgically removed high-risk melanoma. It is not approved, and detailed data are not yet public.
- In glioblastoma, the evidence is early. A University of Florida mRNA vaccine was tested in four patients, and other vaccines are in early trials.
- If you or a family member has cancer, ask your oncologist about registered clinical trials rather than unproven treatments.
mRNA cancer vaccines have passed their first major test in melanoma, but evidence for glioblastoma and other hard-to-treat tumours is still early, and no mRNA cancer vaccine is approved yet.
What is an mRNA cancer vaccine?
Unlike vaccines that prevent infectious disease, these are therapeutic vaccines designed to help treat cancer after it has appeared. They use mRNA technology, but target different antigens. In the individualized approach, a sample of the patient’s tumour is sequenced to find its unique mutations, and a personalized vaccine is made that instructs cells to produce selected tumour neoantigens, which are markers the immune system can learn to attack. Each patient’s dose is made from scratch, and one report puts manufacturing at about six weeks per dose.
The melanoma milestone
The strongest evidence so far comes from melanoma. The Phase 3 INTerpath-001 trial tested intismeran autogene (also called V940 or mRNA-4157) plus pembrolizumab (Keytruda) against pembrolizumab alone in 1,137 patients with completely resected stage IIB to IV melanoma. On August 19, 2026, Merck and Moderna reported meeting their recurrence-free and distant-metastasis-free survival endpoints, the first positive Phase 3 readout for an individualized therapy and an mRNA cancer therapy. It builds on a Phase 2 trial that suggested a 44% reduction in recurrence or death.
Two cautions apply. These are topline announcements, and detailed data have not yet been presented, and the vaccine remains investigational. Wait for peer-reviewed results before treating the size of the benefit as settled.
Why glioblastoma is harder
Glioblastoma is the most aggressive common brain tumour. Median survival is only 14 to 18 months despite surgery, radiation, and chemotherapy. Researchers working on vaccines aim to change the immune environment around the tumour. In a University of Florida study of pet dogs with brain tumours, the vaccine made the tumour’s surroundings “hot” within days, meaning immune cells became active there.
What has been tried in glioblastoma
| Vaccine Candidate / Trial | Development Stage | Summary of Clinical / Pre-Clinical Findings |
| University of Florida RNA-Lipid Particle Vaccine | First-in-human study ($4$ adults) following $10$ pet dog trials | Rapid immune activation within 48 hours (“cold” to “hot” tumour shift); expanded Phase 1 trial planned. |
| CureVac CVGBM | First-in-human dose escalation (MGMT-unmethylated glioblastoma) | Encodes 8 tumor-associated epitopes; $100\,\mu\text{g}$ dose selected for trial expansion. |
| DOC1021 (dubodencel) | Phase 1 dendritic-cell vaccine (loaded with tumour mRNA) | Supported transition to a randomized trial (NCT06805305Utilizes a cell-based approach. |
What we still do not know
- Whether melanoma results carry over. The Phase 3 trial tested a vaccine after surgery, combined with an immune checkpoint drug, in melanoma. It does not show that the approach works in brain tumours.
- The full melanoma data. The size of the benefit and side effects will be clearer when detailed results are presented and peer-reviewed.
- Glioblastoma outcomes. The Florida study included four patients, and the press coverage notes that it is too early to assess clinical effects.
- Speed and cost. Each personalised vaccine is made from the patient’s own tumour and takes weeks to produce. That is a practical hurdle for fast-growing cancers.
- Approval. The companies say they plan to engage regulators on the melanoma result. No mRNA cancer vaccine is approved yet.
The bottom line
mRNA cancer vaccines have moved from idea to a first positive Phase 3 result in melanoma, which is real progress. For glioblastoma and other hard-to-treat tumours, the evidence is early and small, and no mRNA cancer vaccine is approved. Treat headlines about “breakthroughs” as a reason to follow the trials, and talk to an oncologist about options.
Related on Scientifix Digest: The Cancer-Killing Immune Cells That Scientists Just Made Dramatically More Powerful · Scientists Designed a Drug That Crosses Into the Brain
References
https://doi.org/10.3389/fonc.2024.1454370
Pharmaceutical Journal. Personalized vaccine slows melanoma recurrence, suggests topline phase III results. August 2026 (reports the Merck and Moderna statement of August 19, 2026).
Pharmacy Times. Phase 3 Trial Marks First Success for Personalized Therapy in Resected Melanoma. August 19, 2026.